CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
D-cycloserine + distributed treatment +3 moredrug
Likely dose
D-cycloserine + distributed treatment 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00720759
NCT00720759Phase 2Completed

Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine

US Department of Veterans Affairs·interventional·Posted Jul 23, 2008·Updated Mar 7, 2014

In Brief

A Phase 2 clinical trial evaluating D-cycloserine + distributed treatment, D-cycloserine + condensed treatment, and 2 other interventions for Stroke. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Each year 730,000 Americans experience a stroke. Forty percent are left with significant paralysis of one arm. Certain types of physical therapy, for example constraint induced movement therapy (CIMT), have been shown to be effective in improving arm function. However, for most subjects, improvement is modest. In this trial, we test two approaches that may increase the amount of improvement achieved: 1) distributing treatment over a greater amount of time; and 2) adding a drug, d-cycloserine, which theoretically enhances the molecular mechanisms of learning.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 23, 2008
Enrollment StartJul 1, 2009
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 17.9 years ago

Interventions

D-cycloserine + distributed treatmentdrug

Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session

D-cycloserine + condensed treatmentbehavioral

Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session

Placebo + distributed treatmentdrug

Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session

Placebo + condensed treatmentbehavioral

Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session